1	Adverse Outcomes in Pulmonary Tuberculosis patients on Retreatment Regimen: Evaluation
2	of Pharmacokinetic Estimates as Risk Indicators
3	
4	Anant Mohan ¹ , Anuj Bhatnagar ² , Tarang Gupta ¹ , Sunita Kanswal ¹ , Ujjalkumar Das ¹ ,
5	Thirumurthy Velpandian ¹ , Randeep Guleria ¹ and Urvashi B. Singh ^{1*}
6	
7	
8	¹ All India Institute of Medical Sciences, New Delhi, India
9	² Rajan Babu Institute of Pulmonary Medicine and Tuberculosis and Hospital, New Delhi, India
10	
11	*Correspondence to:
12	drurvashi@gmail.com
13	
14	
15	Key words : TDM, ATT, Retreatment regimen, Pharmacokinetics
16	
17	
18	
19	
20	
21	
22	

23 Abstract

Patients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated 24 on re-treatment regimen. These patients are known to have adverse outcomes. This study 25 aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcome. 26 27 Plasma levels of retreatment regimen drugs [Isoniazid(INH), Rifampicin(RIF), Pyrazinamide(PZA), 28 Ethambutol(EMB), and Streptomycin(STM)] compared between treatment were responsive/cured and treatment failure/not-cured patients. Plasma drug levels were analysed 29 30 by LC-MS/MS at different time points in 134 PTB patients on retreatment regimen. Of the 134 31 subjects, 108 were cured, 17 patients developed multi-drug resistant TB (MDR-TB), and 9 patients remained smear positive at treatment completion (8 months). The two-hour plasma 32 levels (C_{2hr}) (geometric mean) were lower in 'Not Cured' subjects compared to 'Cured' subjects 33 Notably, in the 26 'Not Cured' subjects, C_{2hr} plasma levels after first dose at DayO were 34 35 significantly low (INH: 0.86 vs 2.94 μg/ml p≤0.002, RIF: 0.56 vs 2.55 μg/ml p≤0.003, PZA: 1.85 vs 26.58 µg/ml p≤0.000 and EMB: 0.72 vs 1.53 µg/ml p≤0.010). In contrast, STM levels were higher 36 (31.84 vs 18.08 μ g/ml p \leq 0.007). Based on ROC analysis of the data, therapeutic indicator 37 values for successful treatment outcome were C_{2hr} plasma levels of 10.6 µg/ml for PZA, 1.14 38 µg/ml for RIF, 1.86 µg/ml for INH and 1.24 µg/ml for EMB. Therapeutic failure in PTB patients 39 on retreatment regimen is associated with lower plasma drug levels. Therapeutic drug 40 41 monitoring would prove useful to maintain drug levels above the minimum cut-off levels for obtaining favourable clinical outcome. 42

44 Introduction

45	In cases of relapse after a successful anti-tubercular therapy (ATT), loss to follow-up or
46	treatment failure, and in others who have undergone previous treatment to TB (1), the
47	standardised retreatment regimen consisting of Isoniazid(INH/H), Rifampicin(RIF/R),
48	Pyrazinamide (PZA/Z), Ethambutol(EMB/E) and Streptomycin(STM/S) for 2 months, followed by
49	HRZE for 1 month and HRE for 5 months (2)is shown to render poor outcomes(3-5) and one of
50	the reasons postulated for this retreatment failure in patients with TB is the sub-therapeutic
51	ATT drug levels or their low bioavailability (6-10) that can lead to slower treatment response,
52	acquired drug resistance, and relapse (11, 12).
53	Monitoring of plasma levels of drugs to tailor patient's regimen, in a strategy called as
54	'Therapeutic Drug Monitoring' (TDM) has shown promising results in reaching requisite
55	treatment goals in PTB patients (13, 14) . Although TDM has been shown to predict clinical
56	outcomes in treatment-naive PTB (12), no study has exclusively monitored drug levels in PTB on
57	a retreatment regimen. TDM may have important implications for improving outcomes in this
58	group of patients. To address this, we evaluated plasma levels of 5 ATT drugs on Day0 (0 and
59	2hrs after first dose) and after 2, 3, 5 & 8 months of initiation of treatment in subjects who
60	were prescribed PTB retreatment regimen.

- 61
- 62

64 Results

Patients, Treatment Regimens and Outcomes: A total of 134 pulmonary TB patients with past history of TB and ATT medication were enrolled in the study. One hundred twenty one (90.3%) patients agreed to the intermittent ATT schedule. (DOTS as per RNTCP guidelines), while 13 (9.7%) preferred the daily regimen. The demographic details and clinical history of the patients is shown in Table 1 and microbiological testing data is shown in Table 2.

All 134 patients had a confirmed drug-susceptible PTB at the start of treatment. Of these, 108 (80.5%) patients were declared cured of TB and classified as 'Cured'. Nine patients (6.72%) were not TB-free as per microbiological testing or physical examination. Seventeen patients (12.7%) developed Rif resistance (RR) MDR (Multi-drug-resistant TB) by the end of third month of therapy and were referred for MDR regimen. Taken together, these 26 patients were categorized as 'Not Cured'.

Plasma Drug Levels: Plasma levels for H, R, Z, E and S were estimated in all patients for time
 points day0, followed by month 2, 3, 5 and 8 for H, R, E and day0, 2nd month for Z and on day0
 for S.

In the 17 patients who developed RR, plasma levels for H, R, Z, E and S were estimated until 2nd
 and 3rd month depending on time of MDR diagnosis.

A comparison of drug levels between 'cured' and 'not cured' patient groups according to timelines during the treatment is shown in table 3 and figure 1a. Statistically, plasma levels of isoniazid were significantly higher at 0, 2nd, and 5th month time points, rifampicin levels were significantly higher at day0, comparable at month 2nd and higher at 3rd, 5th and 8th months. Pyrazinamide and ethambutol levels were significantly higher at both Day0 and 2nd months. In contrast to the above four drugs, streptomycin levels were found to be significantly higher on day0 in the 'Not Cured' category of patients. Of note, all thirteen patients in the study who had been on daily dosing regimen, were cured after the therapy, while all patients who acquired drug resistance or failed treatment had been on intermittent therapy.

Pharmokinetic variability in patient population: Plasma concentrations were found to be 90 widely distributed in the patients. Overall, the highest drug concentrations were attained on 91 92 $day0-C_{2hr}$ time-point after which most peaks declined with time. Compared to the reference 93 values for adults (15) (16), lower average (GM) drug plasma levels were prevalent at all time points in our study population (Table 3 ,figure 2). 22.3 % (27/121) of patients had plasma 94 concentrations within the reference target range. Only 4/26 'not cured' patients had drug levels 95 within these target ranges and each of these patients achieved 'within range' plasma level for a 96 97 single drug only.

98 Area under the ROC curve and predictor values for C2_{hr}plasma ATT levels

99 Plasma drug levels were significantly lower in 'Not Cured' group when compared to the 'Cured 100 Group' for all ATT drugs at C2_{hr} on day0. Hence we analysed the ROC curves for this time point 101 (Table4, Figure3). The area under the ROC curve were the highest for PZA (0.924) followed by 102 INH (0.788) and RIF (0.77). Optimal cut-off values that predict therapeutic indicator drug levels 103 (minimum levels of drugs that when achieved in patient blood would likely predict a positive treatment outcome) are shown in Table 4. PZA (10.6 µg/ml, 86% sensitivity, 87% specificity) 104 emerged as the best discriminating therapeutic indicator for treatment success in this group of 105 106 patients (Figure 4).

107 Discussion

There is a paucity of studies discussing adverse outcomes in PTB re-treatment subjects. Here, we report a serial estimation of levels of first-line ATT drugs measured at five time-points during therapy and correlated to disease outcome exclusively in 134 PTB re-treatment patients.

We found a subject-wise variability in plasma concentrations of all four TB drugs which is in 111 concordance with many other studies.(9, 15). Majority (68.5%) patients had lower drug 112 concentrations than the reference values (15, 16). In the 'Not Cured' category, C_{2hr} levels of four 113 ATT drugs remained much below reference target ranges for adults almost at all time points 114 during the therapy, and were significantly lower than levels in 'Cured' patients. Patients with 115 extremely low C_{2hr} ATT levels in plasma on day0 had outcomes such as acquired MDR-TB and 116 treatment failure. Post-hoc analysis showed that patients with statistically significant low drug 117 levels (65%) got acquired drug resistance within three months of enrolment in the study. All of 118 119 these patients had lower levels in comparison to both cured and not cured patients (Figure 1b). No statistically significant difference in the drug plasma levels of patients on daily dose as 120 121 compared to those on intermittent dosing was evident; however, the plasma levels were higher 122 in daily dose patients (Figure4). A significant increase in microbiologically defined adverse 123 outcomes in patients on intermittent therapy has been previously reported by Johnston et al. 124 where pooled analysis and meta regression showed that intermittent regimen in ATT was 125 inferior in all 3 outcomes viz. failure, relapse and acquired drug resistance (17). WHO has since 2008 recommended daily dosing (2) and country programs too has now implemented daily 126 127 DOTS therapy (18)

Efficacy of first-line ATT has been shown to strongly associate with area under the curve (AUC). 128 129 AUC derived from 9-time points sampling during the first 24 hrs post-drug administration were predictive of long-term clinical outcomes in PTB patients (12). Microbicidal effects of ATT are 130 131 best described by AUC:MIC and Cmax:MIC ratios (19).Such studies require multiple sampling, 132 are stressful to TB patients and not practical in resource-limited settings. We collected samples at trough concentrations (C_0) and 2 hour concentrations(C_{2hr}) post drug on day0, months 2, 3, 5 133 and 8 in order to identify the best indicator time point for single sampling as drug levels at C_{2hr} 134 135 correlate well with Cmax and/or AUC (15, 16, 20, 21). However, the possibility that low C2_{hr} 136 plasma concentrations could be a result of delayed absorption rather than a low peak concentration and could miss the actual peak concentration Cmax (21) cannot be ruled out. 137

Instead of using predetermined C_{max} concentrations, we first enrolled patients randomly and dichotomized them based on treatment outcomes (clinical with microbiological findings) at the end of the study. Loss to follow-up in a few patients, inability to provide sputum specimens, undetectable plasma drug levels etc. have caused a few gaps in our data. Patients were encouraged to comply and we sought to include all available data for analysis.

Peak drugs levels attained for INH, RIF and PZA reduced with time in our patients in both 'cured' and 'not cured' groups, possibly due to individual pharmacokinetic variations, poor drug absorption, pre-hepatic metabolism and hepatic enzymes induction, drug binding to plasma protein, or drug-drug interactions (22, 23). Rifampicin is reported to be highly bound to plasma proteins in TB patients as well as healthy subjects, leading to a loss in circulating levels, explaining decrease in bioavailability of Rifampicin from 93% to 68% after three weeks of treatment (24-26). It is tempting to hypothesize that drug-drug interaction is at its minimal on

DayO, but may have stronger and complex interactions to compromise drug bioavailability resulting in lower C_{2hr} concentrations subsequently during therapy possibly due to induction of drug metabolism or transporter protein synthesis. DayO- C_{2hr} drug levels for cured patients were higher than subsequent time points except for EMB for which the levels were relatively constant.

We also report therapeutic indicator levels, the minimal drug plasma level values predicting a 155 positive treatment outcome (Table 4) for all the four ATT drugs. We believe that the day $0-C_{2hr}$ 156 157 levels especially that of PZA might be useful as a cut-off reference for dosage adjustments for 158 clinicians during therapy and help mitigate adverse events or treatment failure in DOTS Category II patients early on. Similar to our findings, a recent study where drug exposure and 159 160 MIC were evaluated in PTB patients, PZA levels were shown to be important in predicting poor clinical response suggesting the use of PZA and RIF at levels above a threshold value to improve 161 162 treatment outcomes. However, the inter-play between PZA and RIF may affect the final levels 163 detected.(27)

Evaluation of certain other factors which may contribute to patient outcome was beyond the 164 165 scope of the present study. Improvement in nutritional status and immune response may 166 complement the pharmacotherapy. Low INH concentrations observed in the patients could also 167 be due to the well recognised pharmacogenetic variants with acetylator status (28-30). Another limitation was that we could not delineate the cumulative effects of the drugs or drug-168 drug interference in the regimen. Our study had some missing data due to missing patient visits 169 (follow-up) and few undetectable drug levels in some patients. These, however, will unlikely 170 171 impact the overall results obtained.

172	Overall, we conclude that treatment outcomes in pulmonary tuberculosis patients on
173	retreatment regimen are strongly linked to plasma levels of drugs, with low concentrations
174	leading to poor treatment outcomes. Our findings emphasize the importance of therapeutic
175	drug monitoring and dose adjustment to maintain plasma levels above a critical threshold.

176

177 Methods and Materials

178 Ethics: This study was done at the All India Institute of Medical Sciences (AIIMS), New Delhi,

179 India from 2012-2014 and approved by the Institutional Ethics Committee, AIIMS (IEC/NP-

```
180 251/2012&RP-22/2012)
```

Patients : Patients diagnosed with drug susceptible PTB (and no other co-morbidities), aged between 15 to 65 yrs and advised the retreatment regimen under National TB Elimination Program (NTEP) (erstwhile Revised National TB Control Program (RNTCP) were included in this study (31) . Informed written consent was obtained from each patient.

A detailed demographic data and clinical history was obtained (Table 1), and results of sputum acid-fast stains, cultures and all laboratory data were recorded (Table 2). A brief diagram of the study approach is shown in supplementary figure S1.

Treatment Regimen: ATT was given as per the prevailing guidelines of the RNTCP at the time of the study (2012-2014) for previously treated TB cases (erstwhile Category II) i.e., INH + RIF+ EMB + PZA + injectable STM for 2 months, followed by INH + RIF+ EMB + PZA for 1 month, and INH + RIF+ EMB for 5 months as per the weight bands.(H,5mg/Kg, R,10 mg/Kg, Z,30 mg/Kg, E,15 mg/Kg, S,15 mg/Kg(in daily regimen) and H,10 mg/Kg, R,10 mg/Kg, Z,30 mg/Kg, E,15

mg/Kg, S,15 mg/Kg (intermittent regimen). RNTCP followed intermittent regimen
recommended by WHO (2),Clinical follow-up of patients was done at 0 day, weeks 2, 4, 8, 12,
20, and 32 (at completion of 8 months). Therapy was not modified during the study.

196 Sample collection

Sputum samples: For AFB smear, MGIT culture and Xpert MTB/RIF assays, 10 ml sputum sample
was collected from study subjects at the time of recruitment (Day0) and at the end of 2, 3, 5 and
8 months.

Blood samples: Half ml blood sample was collected for the measurement of baseline drug concentration just before intake of daily dose of ATT and define the trough of drug level, on all days of sample collection. ATT medicines were given under observation of the field worker before breakfast as prescribed, following which the second blood sample (0.5 ml) was collected at 2 hours from the time of drug intake. Blood samples were collected in polypropylene BD vacuutainers containing EDTA and sodium ascorbate. Separated plasma was stored in plain endotoxin free vials at -80°C for further use.

207 **Samples processing and AFB-staining:** Samples were processed for decontamination by 208 Modified Petroff's method and stained for acid fast bacilli by Ziehl-Neelson's staining as per 209 standard protocol (32)

Culture for *Mycobacterium tuberculosis*: Concentrated sediment from decontaminated sample
 was inoculated in MGIT 960 medium (BD Biosciences) and cultured for *Mycobacterium tuberculosis* (MTB) using standard MGIT[™] method as per manufacturer's instructions (Beckton
 Dickinson, MD, USA)

214 Xpert MTB/RIF Assay

215 Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) was used for detection of MTB and
216 resistance to Rifampicin, as per manufacturer's instructions.

217 LC-MS/MS and C_{max}determination

Level of drugs in plasma samples were analysed by Liquid chromatography-tandem mass 218 219 spectrometry (LC-MS/MS) as described previously (33). An Ultra High Performance Liquid 220 Chromatographic system (UHPLC, Thermo Surveyor system, CITY, USA) coupled with a triple 221 quadrupole mass spectrometer API-4000 QTrap fitted with Turbo Ion Spray Ionization (ESI) 222 source (MDS SCIEX, Applied Biosystems, USA) was operated in positive ion mode for separation 223 and detection of drug concentrations of the anti-tuberculosis drugs (H, R, E, Z and S). Standards 224 were procured from Sigma-Aldrich Ltd, India and the validation of the analytical method was done as per United States Food and Drug Administration (US-FDA) guidelines for bioanalytical 225 226 method validation (U.S. Food & Drug Administration, 2013).

Pharmacokinetic parameters of C_{0hr} were measured for baseline plasma drug concentration and C_{2hrs} for steady state C_{max} plasma concentration. The 2-hour plasma concentrations were compared with the reference C_{2hr} concentrations as described previously (15, 16)

Evaluation of Treatment Response: Patients were defined as 'cured' if their sputum were AFBnegative within 5 months of treatment and continued to be negative until the end of treatment along with the physician's clinical assessment of TB free status. 'Not Cured' status was defined as presence of a positive AFB smear beyond 5 months of a compliant tuberculosis treatment, presence of a drug-resistant strain during any point of treatment, or a physician's evaluation of

235 symptoms and clinical status after 5 months of treatment compared with the status at236 diagnosis. (31)

Statistical Analysis: Data were recorded and analysed using MS-Excel-2007 and SPSS 22.0 for 237 Windows[®] (SPSS Inc., Chicago, IL, USA).Chi-square tests were used to investigate any 238 239 association of patient demography with clinical outcomes. Geometric mean (GM) plasma concentrations between the patients groups were compared using one way ANOVA and Mann 240 Whitney U tests. Receiver operator characteristics (ROC) curves were used to study the 241 242 discriminatory abilities of ATT plasma levels between the two categories and optimal cut off for 243 therapeutic indicator levels (TIL). All tests were two sided, with $P \le 0.05$ indicating a statistically significant difference. 244

245

246 Acknowledgement

We are thankful to our patients for the success of this study. We also thank Mr. Ashish Datt Upadhayay, Statistical Assistant, Department of Biostatistics, AIIMS, New Delhi for the ROC curve analysis.

250 We thank DST-FIST for providing liquid chromatography coupled tandem mass spectroscopy 251 facility for the analysis.

252

253 References

WHO. 2013; updated Dec 2014 and Jan 2020. Definitions and reporting framework for
 tuberculosis—2013 revision. World Health Organisation Switzerland, Geneva.

- 256 2. WHO. 2010 (updated 2017). Treatment of Tuberculosis Guidelines,4th edition
- 257 Organisation WH, Geneva, Switzerland.
- 3. Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo
- 259 G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R,
- 260 Elliott AM, Ellner JJ, Smith PG, Mugerwa RD. 2011. Effectiveness of the standard WHO
- 261 recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a
- 262 prospective cohort study. PLoS Med 8:15.
- 4. Cohen DB, Davies G, Malwafu W, Mangochi H, Joekes E, Greenwood S, Corbett L, Squire
- 264 SB. 2019. Poor outcomes in recurrent tuberculosis: More than just drug resistance? PLoS 265 One 14.
- 266 5. Sisodia RS, Wares DF, Sahu S, Chauhan LS, Zignol M. 2006. Source of retreatment cases
- 267 under the revised national TB control programme in Rajasthan, India, 2003. Int J Tuberc
- Lung Dis 10:1373-9.
- 269 6. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum
- antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-
- 271 83.
- 272 7. Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS, Ind PW, McKenna C.
- 273 1996. Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary
- 274 tuberculosis. Bmj 313:1543-5.
- 275 8. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow
- 276 response to tuberculosis treatment in a state control program, Virginia, USA. Emerg
- 277 Infect Dis 16:1546-53.

278	9.	Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL,
279		Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and
280		pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-
281		infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-94.
282	10.	Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. 2015. Serum Levels
283		of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
284		Antimicrob Agents Chemother 60:92-8.
285	11.	Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant
286		tuberculosis not due to noncompliance but to between-patient pharmacokinetic
287		variability. J Infect Dis 204:1951-9.
288	12.	Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug
289		concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-73.
290	13.	Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W,
291		van Soolingen D, Alffenaar JW. 2016. Current status and opportunities for therapeutic
292		drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol
293		12:509-21.
294	14.	Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di
295		Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and
296		PBMCs. Br J Clin Pharmacol. 2017 May;83(5):1146-1148. doi: 10.1111/bcp.13196. Epub
297		2017 Jan 18.
298	15.	Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs

299 62:2169-83.

300	16.	Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van
301		Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma
302		concentrations in relation to treatment response in Indonesian pulmonary tuberculosis
303		patients. Antimicrob Agents Chemother 57:3614-9.
304	17.	Johnston JC, Campbell JR, Menzies D. 2017. Effect of Intermittency on Treatment
305		Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.
306		Clin Infect Dis 64:1211-1220.
307	18.	NTEP (National Tuberculosis Elimination Programme fRNTCP, RNTCP). 2017 March.
308		National Strategic Plan for Tuberculosis: 2017-25 Elimination by 2025. Welfare MoHwF,
309		Ministry of Health with Family Welfare, Nirman Bhawan, New Delhi.
310		https://tbcindia.gov.in/WriteReadData/National%20Strategic%20Plan%202017-25.pdf.
311	19.	Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults:
312		current standards and recent advances. Insights from the Society of Infectious Diseases
313		Pharmacists. Pharmacotherapy 29:1468-81.
314	20.	Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse
315		RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.
316		2019. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line
317		Tuberculosis Drugs in Patients with Tuberculosis. Clin Pharmacokinet 58:1445-1454.
318	21.	Peloquin CA. 1997. Using therapeutic drug monitoring to dose the antimycobacterial
319		drugs. Clin Chest Med 18:79-87.
320	22.	Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. 1987. Influence of the enzyme
321		induction by rifampicin on its presystemic metabolism. Pharmacol Ther 33:201-4.

322	23.	Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985.
323		Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin
324		Wochenschr 63:1205-11.
325	24.	Peloquin CA. 2001. Pharmacological issues in the treatment of tuberculosis. Ann N Y
326		Acad Sci 953:157-64.
327	25.	Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH,
328		Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA,
329		Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A,
330		Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. 2016. Official
331		American Thoracic Society/Centers for Disease Control and Prevention/Infectious
332		Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible
333		Tuberculosis. Clin Infect Dis 63:e147-e195.
334	26.	Boman G, Ringberger VA. 1974. Binding of rifampicin by human plasma proteins. Eur J
335		Clin Pharmacol 7:369-73.
336	27.	Zheng X, Bao Z, Forsman LD, Hu Y, Ren W, Gao Y, Li X, Hoffner S, Bruchfeld J, Alffenaar
337		JW. 2020. Drug exposure and minimum inhibitory concentration predict pulmonary
338		tuberculosis treatment response. Clin Infect Dis 18.
339	28.	Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug
340		metabolism. Annu Rev Pharmacol Toxicol 37:269-96.
341	29.	Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ,
342		Aarnoutse RE. 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian
343		patients. Antimicrob Agents Chemother 57:3208-13.

344	30.	Aarnoutse R. 2011. Chapter 18: Pharmacogenetics of Antituberculosis Drugs, vol vol 40.
345		Basel, Karger.
346	31.	NTEP (National Tuberculosis Elimination Programme fRNTCP, RNTCP). 2016. Technical
347		and Operational Guidelines for TB Control in India Directorate General of Health
348		Services MoHaFW, Nirman Bhawan, Central TB Division, New Delhi - 110001.
349	32.	RNCTP. April 2009. Training Manual for Mycobacterium tuberculosis Culture & Drug
350		susceptibility testing. Directorate General of Health Services MoHaFW, Nirman Bhawan,
351		Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110011,
352	33.	Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. 2016.
353		Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected
354		Indian children. Int J Tuberc Lung Dis 20:666-72.
355		
356		
357		
358		
359		
360		
361		
362		

363	Tables
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	

207			
387	Characteristics	Statistics	Total (n*)
388	Age		101
	Age (years)	33.5 <u>+</u> 12.5 (15-65)	131
389	Gender		
390	Male	87 (64.9%)	134
	Female	47 (35.1%)	
391	Retreatment Category		
202	Relapse	77(57.5%)	
352	Treatment after Default	18(13.4%)	124
393	Treatment Failure	10(7.5%)	
	Others	19(14.2%)	
394	Smoking History		
395	Non Smoker	73(54.5%)	
	Ex Smoker	18(13.4%)	117
396	Smoker	26(19.4%)	11/
307	MSI **- Ex Smokers	219.47±265.63	
357	MSI** - Smokers	391.78 ± 810.34	
398	Other History		
	Alcohol intake	44(32.8%)	116
399	Family History of TB	19(14.2%)	
400	Clinical Data –Symptoms		
	Cough	98(73.1%)	118
401	Fever	65(48.5%)	114
402	Dyspnea	66(49.3%)	117
402	Expectoration	60(44.8%)	112
403	Hemoptysis	28(20.9%)	114
	Night Sweats	16(11.9%)	111
404	Weight Loss	91(67.9%)	118
405	Loss of appetite	90(67.2%)	117
	Diarrhea	6(4.5%)	112
406	BMI*** (mean <u>+</u> SD) kg/m ²	17.9 <u>+</u> 3.6 (10.6-	70
407		31.8)	/8
-07	ATT schedule during study		
408	Daily	13(9.7%)	134
400	Intermittent	121(90.3%)	
409			

Table 1: Basic Demographic and Clinical Details of Study Population

410 Data are presented as absolute numbers, percentage (%) or mean (±SD).

- 411 *number of data available/recorded
- **MSI- Mean Smoking Index –Calculated as multiplication of the average number of cigarettes
 smoked per day with duration (in years).
- 414 ***BMI, Body Mass Index (weight in kilograms divided by the square of the height in meters)
- 415
- 416
- 417

418

Table 2: PTB DOTS Category II Patients – Microbiological Diagnosis Details

		Time Point	Tostod	Positivo	Negative	MDB
419	Test	(month)	(n)	(n)	(n)	(n)
		(monen)	(11)	('')	(")	(11)
420		0	132 [§]	105 (79.55%)	27(20.45%)	0
		2	83	9 (10.84%)	74(89.16%)	4
421	AFB Smear*	3	79	8 (10.13%)	71(89.87%)	17**
472		5	81	26 (32.10%)	55(67.90%)	
722		8	47	2 (4.26%)	45(95.74%)	
423	MGIT Culture***	0	133 §	88 (66.17%)	45(33.83%)	

424 *AFB, acid-fast bacilli

- 425 **Cumulative number of patients
- 426 ***MGIT Mycobacteria Growth Indicator Tube
- 427 [§] For One patient MGIT was not done and in two patients AFB smear data was missing
- 428
- 429
- 430
- 431
- 432
- 433
- 434

Table 3: Plasma drug levels at 2 hrs post administration of ATT in DOTS category II P patients						
Time Point Drug (month)			Cured	t Cured		
U	. ,		Plasma levels		Plasma levels	
		n*	(µg/ml)**	n*	(µg/ml)**	p value
	0	87	2.94(0.161-12.80)	17	0.86(0.06-8.27)	0.002 [§]
	2	68	1.56(0.019-9.89)	14	0.58(0.14-3.07)	0.009 [§]
ISONIAZID	3	67	1.46(0.0331-12.30)	8	0.55(0.05-4.84)	0.172
	5	51	1.97(0.0934-13.90)	9	0.24(0.00-2.94)	0.031 [§]
	8	36	1.00(0.0352-6.75)	3	0.25(0.02-1.01)	0.283
	0	79	2 55(0 00268-20 20)	16	0 56(0 05-12 70)	0.003§
	2	54	1 26(0 0802-14 80)	9	1 31(0 19-9 01)	0.689
RIFAMPICIN	3	55	1 44(0 0017-23 30)	5	0.29(0.01-1.49)	0.005
	5	46	1.39(0.00384-37.50)	8	0.24(0.04-2.87)	0.144
	8	31	1.32(0.0643-25.50)	3	0.25(0.06-1.68)	0.380
	0	00		4 5		0.000
PYRAZINAMIDE	0 2	88 71	26.58(1.03-81.60) 17.72(0.105-181.0)	15 14	1.85(0.06-30.50)	0.000 ^s 0.002 [§]
			х <i>У</i>		· · · · · ·	
	0	88	1.53(0.0803-11.80)	17	0.72(0.18-2.15)	0.010 [§]
	2	70	1.47(0.115-18.00)	14	0.66(0.16-2.19)	0.043 [§]
ETHAIVIDUTUL	3	68	1.56(0.0365-19.80)	8	1.11(0.22-5.07)	0.332
	5	53	1.18(0.0676-22.90)	9	0.25(0.03-2.38)	0.137
	8	36	1.56(0.00813-22.50)	3	0.64(0.08-3.26)	0.344
					21 9//1 07	
STREPTOMYCIN	0	83	18.08(0.059-73.60)	19	31.04(1.07- 100.00)	0.007 [§]
	Drug ISONIAZID RIFAMPICIN PYRAZINAMIDE ETHAMBUTOL	Time Point (month)Drug0 2 3 5 8ISONIAZID0 2 3 5 8RIFAMPICIN0 2 8PYRAZINAMIDE0 2 8PYRAZINAMIDE0 2 3 5 8ETHAMBUTOL0 3 5 8	Time Point (month) Time Point (month) ISONIAZID 0 87 ISONIAZID 0 87 2 68 3 3 67 5 5 51 8 8 36 0 7 5 51 8 36 79 2 54 3 3 55 46 8 31 79 2 54 3 3 55 46 8 31 71 9 88 2 71 8 36 8 36 2 70 3 68 5 53 8 36	Time Point Drug Cured (month) 0 87 2.94(0.161-12.80) 1SONIAZID 0 87 2.94(0.161-12.80) 2 68 1.56(0.019-9.89) 3 67 1.46(0.0331-12.30) 5 51 1.97(0.0934-13.90) 8 36 1.00(0.0352-6.75) 0 79 2.55(0.00268-20.20) 2 54 1.26(0.0802-14.80) 3 55 1.44(0.0017-23.30) 5 46 1.39(0.00384-37.50) 8 31 1.32(0.0643-25.50) PYRAZINAMIDE 0 88 26.58(1.03-81.60) 2 71 17.72(0.105-181.0) 2 6 1.56(0.0365-19.80) 3 68 1.56(0.0365-19.80) 5 53 1.18(0.0676-22.90) 8 36 1.56(0.00813-22.50)	Table 3. Plasma drug levels at 2 ms post administration of P patients Time Point Cured No Plasma levels n* (µg/ml)** n* plasma levels n* n* Queed to the point (month) ISONIAZID 0 87 2.94(0.161-12.80) 17 ISONIAZID 0 87 2.94(0.161-12.80) 17 ISONIAZID 0 87 2.94(0.161-12.80) 17 ISONIAZID 2 68 1.56(0.019-9.89) 14 3 67 1.46(0.0331-12.30) 8 5 5 B 36 1.09(0.0352-6.75) 3 3 5 144(0.0017-23.30) 5 RIFAMPICIN 2 54 1.26(0.0803-14.80) 9 3 5 3 55 1.44(0.0017-23.30) 5 2 71 1.772(0.105-181.0) <t< td=""><td>Time Point (month) Cured Plasma levels (µg/ml)** Not Cured 0 87 2.94(0.161-12.80) 17 0.86(0.06-8.27) 1SONIAZID 2 68 1.56(0.019-9.89) 14 0.58(0.14-3.07) 3 67 1.46(0.0331-12.30) 8 0.55(0.05-4.84) 5 51 1.97(0.0934-13.90) 9 0.24(0.00-2.94) 8 36 1.00(0.0352-6.75) 3 0.25(0.02-1.01) RIFAMPICIN 2 54 1.26(0.0802-14.80) 9 1.31(0.19-9.01) 3 55 1.44(0.0017-23.30) 5 0.29(0.01-1.49) 5 8 31 1.32(0.0643-25.50) 3 0.25(0.06-1.68) PYRAZINAMIDE 0 88 26.58(1.03-81.60) 15 1.85(0.06-30.50) 2 71 17.72(0.105-181.0) 14 1.01(0.04-6.43) ETHAMBUTOL 0 88 1.53(0.0803-11.80) 17 0.72(0.18-2.15) 3 68 1.56(0.0365-19.80) 8 1.11(0.22-5.07) 1.47(0.115-18.00)</td></t<>	Time Point (month) Cured Plasma levels (µg/ml)** Not Cured 0 87 2.94(0.161-12.80) 17 0.86(0.06-8.27) 1SONIAZID 2 68 1.56(0.019-9.89) 14 0.58(0.14-3.07) 3 67 1.46(0.0331-12.30) 8 0.55(0.05-4.84) 5 51 1.97(0.0934-13.90) 9 0.24(0.00-2.94) 8 36 1.00(0.0352-6.75) 3 0.25(0.02-1.01) RIFAMPICIN 2 54 1.26(0.0802-14.80) 9 1.31(0.19-9.01) 3 55 1.44(0.0017-23.30) 5 0.29(0.01-1.49) 5 8 31 1.32(0.0643-25.50) 3 0.25(0.06-1.68) PYRAZINAMIDE 0 88 26.58(1.03-81.60) 15 1.85(0.06-30.50) 2 71 17.72(0.105-181.0) 14 1.01(0.04-6.43) ETHAMBUTOL 0 88 1.53(0.0803-11.80) 17 0.72(0.18-2.15) 3 68 1.56(0.0365-19.80) 8 1.11(0.22-5.07) 1.47(0.115-18.00)

453

454 Time point 0 represents day of initiation of therapy.

455 *number of data available/recorded

456 ** C2hr data from subjects (on intermittent regimen) was log transformed and is presented as

457 the geometric mean along with range (minimum-maximum) in μ g/ml

458 §Values indicate significant differences between cured and not cured groups (P ≤0.05) by one

459 way ANOVA

PTB patients on Retreatment regimen								
ATT Drug	n	Area under the	[95% CI]	Optimal Cut off *	Sensitivity	Specificity		
		Curve		(µg/ml)		464		
ISONIAZID	104	0.788	[0.67-0.90]	1.86	0.71	0.82		
RIFAMPICIN	95	0.770	[0.65-0.89]	1.14	0.77	0.75 ⁴⁶⁵		
PYRAZINAMIDE	103	0.924	[0.84-1.00]	10.6	0.86	0.87		
ETHAMBUTOL	105	0.712	[0.60-0.83]	1.24	0.60	0.76		
STREPTOMYCIN	102	0.684	[0.54-0.83]	38.0	0.63	0.6 4 67		
						468		

Table 4. Receiver operator characteristics (ROC) values for plasma levels of ATT i#61 PTB patients on Retreatment regimen

Table shows accuracy of area under the curve for C2hr plasma levels of ATT in PTB patients onretreatment regimen

- 471 *Optimal cut off values (column 4) or Therapeutic indicator levels (minimum plasma drug
- 472 concentrations that predict a positive treatment outcome ('Cured') in the study population).

- -TUJ

485

Figure legends

486 Figure 1: Serum levels (ug/ml) at different time points for Category II retreatment regimen

487 drugs in PTB patients

488 Figure 1: a). ATT Plasma levels in Cured and Not Cured PTB patient groups. b) ATT Plasma levels in Cured, Rifampicin resistant (RR)MDR and Rifampicin sensitive (RS)Not Cured- groups. X axis 489 shows time points of drug administration i.e. day 0, 2 month, 3 month, 5 month and 8 month 490 (0, 2, 3, 5 and 8 - fig1a) or day 0,2nd month and 3rd month (0, 2 and 3 -fig1b). Y-axis shows 491 geometric mean of plasma drug concentrations (µg/ml) of INH, RIF, PZA, EMB and STM as 492 measured by HPLC-MS in patient blood samples after 2hrs of drug ingestion on day 0. 493 Pyrazinamide is shown for 2 months and streptomycin C_{2hr} levels are shown for day 0 time 494 point as per the treatment regimen. 495

Solid line shows data from Cured subjects and dotted line shows data from Not-cured patients.
+ represents therapeutic indicator levels i.e. Oday-C_{2hr} levels required for a successful treatment
outcome from cut off predicted from ROC analysis . Statistical significance is as shown in Table
3.

500 Figure 2. Pharmacokinetic variability of isoniazid, rifampicin, pyrazinamide and ethambutol 501 in PTB patients on retreatment regimen at Day0-C_{2hr}.

Figure 2. Figure shows the percentage of patients with very low, low and target (high) serum
 concentrations at C2_{hr} on Day0 of drug dose administration in 'cured' and 'not cured' groups for
 isoniazid, rifampicin, pyrazinamide and ethambutol.

505 Values are in comparison to adult reference ranges as reported previously (17) (18)

506	Target ranges:	H- 3–6 μg/n	ml , R- 8–24 μg,	/ml , Z- 20-50 μg/	'ml_and E- 2–6 μg/	ml (17)
-----	----------------	-------------	------------------	--------------------	--------------------	---------

- 507 Low plasma concentrations: $H < 3\mu g/ml$, $R < 8\mu g/ml$, $Z < 35 \mu g/ml$ and $E < 2 \mu g/ml$.
- 508 Very low plasma concentrations: $H < 1.5 \mu g/ml$, $R < 4 \mu g/ml$, $Z < 20 \mu g/ml$ and $E < 1 \mu g/ml$
- 509 (18)

510 Figure 3: ROC Analysis of ATT drugs in PTB patients onretreatment regimen

511 Figure 3: Figure shows ROC curve analysis of Day0-C_{2hr} plasma levels of ATT-drugs, isoniazid

512 (INH), rifampicin (RIF), pyrazimanide (PZA), ethambutol (EMB) and streptomycin (STM) in PTB

513 patients on retreatment regimen. Values are as given in table 4.

514 **Figure 4: Daily vs intermittent regimen in PTB patients.**

515 Figure 4: Plasma levels of ATT drugs INH, RIF, PZA, EMB and STM at different time points of Daily vs Intermittent/Alternate Day regimen in PTB patients. X axis shows time points of drug 516 administration i.e. day 0, 2 month, 3 month, 5 month and 8 month (0, 2, 3, 5 and 8).Y-axis 517 518 shows Geometric Mean of plasma drug concentration (µg/ml) as measured by LC-MS in patient blood samples after 2hrs of drug ingestion. Solid line (--) represents plasma levels of daily 519 520 521 denotes statistical significance $p \le 0.05$ Pyrazinamide is shown for upto 2 months and streptomycin C_{2hr} levels are shown for Day0 522

523 Figure S1: Study Approach:

524 Figure illustrates a schematic design of the study from patient enrolment until statistical 525 analysis

526	Figures
527	
528	
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	









